Purpose: The objective of the present study was to evaluate the effects of inhaled tiotropium on pulmonary function and left ventricular diastolic function in chronic obstructive pulmonary disease patients ≥1 year after pulmonary resection for lung cancer. Methods: This prospective single-arm analysis involved 21 chronic obstructive pulmonary disease patients who underwent pulmonary resection for lung cancer at least one year earlier. Blood pressures, heart rate, spirometry, transthoracic echocardiography including tissue Doppler imaging, and quality of life were evaluated prior to and after 3 months of inhaled tiotropium treatment. B-type natriuretic peptide, white blood cell counts, and C-reactive protein levels before and after inhaled tiotropium treatment were also examined. Results: There were no significant differences between before and after treatment in forced vital capacity and left ventricular ejection fraction. Forced expiratory volume in 1 second and early transmitral velocity/tissue Doppler mitral annular early diastolic velocity values improved from 1.60 ± 0.5 L and 8.97 ± 1.6, respectively, before treatment, to 1.84 ± 0.5 L and 7.59 ± 1.4, respectively, 3 months after treatment (P <0.001). Conclusion: Treatment with inhaled tiotropium may be effective in improving not only pulmonary function but also left ventricular diastolic function of patients with chronic obstructive pulmonary disease in the chronic phase after pulmonary resection.
Introduction
Left ventricular (LV) diastolic dysfunction has been reported in chronic obstructive pulmonary disease (COPD) patients. 1) Lung cancer patients with COPD suffer from dyspnea long after pulmonary resection. LV diastolic dysfunction has been associated with dyspnea in heart failure patients with preserved ejection fraction. 2) As a technique to detect LV diastolic function, tissue Doppler imaging is a useful modality that can be used directly to measure myocardial velocity with high temporal and spatial resolution. Several studies have demonstrated that the ratio of peak early diastolic mitral flow velocity (E) to peak early diastolic mitral annular movement velocity (e'), the E/e' ratio, increases with the elevation of the LV filling pressure that occurs due to impaired LV diastolic function without pseudonormalization, which is observed in the conventional pulsed-wave Doppler parameter. 3, 4) Therefore, E/e' is proposed as a first-line diagnostic index for heart failure with normal LV ejection fraction and diastolic dysfunction in the consensus statement published by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. 5) Bronchodilators are central to the management of stable COPD. 6) Recent reports indicated that treatment with tiotropium, a long-acting inhaled anticholinergic drug, improved dyspnea and lung function compared with placebo. 7) Tiotropium has been reported to improve dynamic hyperinflation in COPD patients. 8) Since LV diastolic dysfunction has been associated with hyperinflation in COPD patients, 9) it is plausible to expect that tiotropium will affect LV diastolic function. However, the effects of tiotropium on LV diastolic function have not been clear.
A prospective pilot study was performed to determine whether tiotropium could improve not only pulmonary function but also LV diastolic dysfunction in lung cancer patients with COPD in the chronic phase after pulmonary resection.
Materials and Methods

Study design
Of 448 patients who underwent a pulmonary resection procedure with anterolateral thoracotomy for lung cancer at National Toneyama Hospital from April 2006 to March 2008, this prospective pilot study included 74 COPD patients who underwent pulmonary resection at least one year earlier and had no cancer recurrence. Exclusion criteria for the present analysis were cardiac rhythm other than sinus, antiarrhythmic drug use, thyroid dysfunction, renal failure requiring hemodialysis, and recent (<1 month) angina pectoris, myocardial infarction, or pneumonia. We also excluded patients who had undergone a lesser resection (wedge resection or segmentectomy) or a more extensive resection (bilobectomy, pneumonectomy, chest wall resection, or major vascular resection). As a result, 22 patients were excluded. Of the remaining 52 patients, 21 patients who suffered from dyspnea and gave their informed consent were offered treatment with inhaled tiotropium bromide (18 µg once daily).
All patients had an Eastern Cooperative Oncology Group performance status of 1 and a smoking history of more than 20 pack-years. Airflow limitation was assessed by spirometry and was defined as a post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV 1 /FVC) <0.70. COPD severity was classified using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. 6) Spirometry was performed by a trained technician according to the American Thoracic Society/European Respiratory Society guidelines. 10) Patients diagnosed with respiratory disorders other than COPD, such as asthma, were excluded. Two-dimensional echocardiographic measurements were obtained based on the recommendations of the American Society of Echocardiography using an ultrasonic device (SONOS 7500: Philips, Andover, MA). Images were obtained from parasternal views and an apical four-chamber view. The patient was placed in the left lateral decubitus position for the parasternal views and the supine position for the apical four-chamber view. The results were analyzed by an echo-cardiologist blinded to all clinical, hemodynamic, and laboratory findings. LV endsystolic and end-diastolic diameters were measured by M-mode echocardiography from the left parasternal short and long axis views. LV mass was calculated using the Devereux formula 11) and indexed to body surface area. LV ejection fraction was determined using the Teicholz formula. Pulmonary arterial systolic pressure (PASP) was predicted from tricuspid regurgitation using the method of Currie and coworkers. 12) Pulsed Doppler transmitral flows, including peak early diastolic mitral flow velocity to peak mitral flow velocity at atrial contraction (E/A ratio), were obtained from the apical four-chamber view, and e' at the septal annular site was obtained using tissue Doppler imaging as previously described. 13) The patients underwent spirometry, transthoracic echocardiography including tissue Doppler imaging, and a quality of life (QOL) questionnaire prior to and after 3 months of inhaled tiotropium treatment. B-type natriuretic peptide (BNP), white blood cell (WBC) counts, and C-reactive protein (CRP) levels before and after 3 months of inhaled tiotropium treatment were also examined. The patients were questioned individually by the same two experienced interviewers at each site at both the initial and follow-up visits, and then grades for dyspnea were selected on the baseline dyspnea index (BDI) and the transitional dyspnea index (TDI). 14) Lower scores in the BDI (range, 0 to 12) represent breathlessness. Higher scores in the TDI (range, −9 to +9) represent less breathlessness as compared to the baseline. Complete follow-up data were obtained for all patients. The study protocol was approved by the Institutional Review Board of National Toneyama Hospital, and all patients provided their written informed consent before participation (trial registration number: JPRN-UMIN000001523).
Statistical analysis
Data were expressed as means ± SD or as proportions. Comparisons among all parameters were analyzed using Student's t-test. All data were analyzed using SPSS version 11.0 (SPSS Inc., Chicago, IL). Probability values of <0.05 were considered significant.
Results
The patients' clinical and surgical characteristics are summarized in Table 1 . There were no patients who received new medication without tiotropium during the study period. None of the subjects had the inhaled tiotropium discontinued due to any side effects, and none had any cardiopulmonary events during the study period.
There were no significant differences between before and after treatment in blood pressures, heart rate, and FVC ( Table 2) . Three months of treatment with tiotropium significantly improved FEV 1 and %FEV 1 compared with before treatment. Residual volume (RV) and the ratio of residual volume to total lung capacity (RV/TLC) were relatively lower after treatment than before treatment, but there were no significant differences. There were no significant differences between before and after treatment with inhaled tiotropium in LV ejection fraction and LV mass index. Three months of treatment with tiotropium significantly improved PASP and E/e' compared with before treatment (Fig. 1) .
WBC counts and CRP levels were relatively lower after than before treatment, but there were no significant differences. There was no significant difference between before and after treatment in BNP levels.
All patients had mild dyspnea with activities of daily living at baseline (BDI score 7.1 ± 1.8). TDI scores showed improved QOL scores after treatment with inhaled tiotropium (mean total TDI score, + 1.2 ± 1.1). A 1-unit change in the TDI has been confirmed to be clinically important.
15) Therefore, the study population was considered to have improved dyspnea-related QOL.
Discussion
The present results are the first to show that treatment with inhaled tiotropium has a beneficial effect on LV diastolic dysfunction in COPD patients in the chronic phase after pulmonary resection for lung cancer. Treatment with inhaled tiotropium did not significantly change FVC and LV ejection fraction, but it improved %FEV 1 , PASP, and E/e', which suggest attenuation of air trapping associated with the improvement of right ventricular overload and LV diastolic dysfunction. The present findings indicate that tiotropium might be a valuable treatment option to improve dyspnea in COPD patients via not only pulmonary function but also cardiac function.
LV diastolic dysfunction has been frequently reported in COPD patients. 1) Older age, hypertension, female sex, diabetes, and obesity have been identified as risk factors for LV diastolic dysfunction. 16) However, COPD has not been widely known as a risk factor for LV diastolic dysfunction. Conventional echocardiographic assessment of LV diastolic function, the E/A ratio, does not reflect diastolic dysfunction in patients with a normal LV ejection fraction. 17) Thus, LV diastolic dysfunction may have been missed in most COPD patients with a preserved ejection fraction. In this study, the effects of inhaled tiotropium on LV diastolic dysfunction were evaluated using tissue Doppler imaging in COPD patients after pulmonary resection for lung cancer. PASP and E/e' are improved from 38.5 ± 5.6 mmHg and 8.97 ± 1.6, respectively, before treatment, to 33.0 ± 3.6 mmHg and 7.59 ± 1.4, respectively, 3 months after treatment (P <0.01 and P <0.001).
Tiotropium is considered to have various effects on LV diastolic dysfunction in COPD patients in the chronic phase after pulmonary resection. First, pulmonary hyperinflation has been reported to cause impaired LV filling. 9) In this study, treatment with tiotropium significantly improved FEV 1 and %FEV 1 and tended to improve RV and RV/TLC. Tiotropium may attenuate air trapping and pulmonary hyperinflation, leading to a reduction of intrathoracic pressure, including pressure on the whole heart.
Secondly, right ventricular overload has been reported to cause LV diastolic dysfunction via the ventricular septum.
18) Some recent studies found that patients with right ventricular pressure or volume overload had a leftward shift of the ventricular septum toward the center of the LV cavity, resulting in geometric distortion of the left ventricle. 18) In this study, PASP was significantly lower after than before treatment. Tiotropium may attenuate right ventricular overload, leading to the reduction of pressure on the left ventricle via the ventricular septum.
Finally, COPD is not simply a lung disease but a type of systemic inflammatory disease. Systemic inflammation may be the missing link between COPD and its extrapulmonary manifestations. 19) Some recent studies have indicated that impaired pulmonary function has been associated with increased levels of systemic inflammatory markers, such as CRP and tumor necrosis factor-alpha. 20) These inflammatory factors have been reported to have a pathogenic role in the development of LV diastolic dysfunction. 21) Recent reports have suggested that tiotropium bromide has anti-inflammatory activity via the muscarinic M3 receptor. 22) In this study, WBC counts and CRP levels were relatively lower after than before treatment, but there were no significant differences because their values were within normal ranges even before treatment. These results suggest that tiotropium inhibits systemic inflammatory reactions, which might lead to beneficial effects on LV diastolic dysfunction.
LV diastolic dysfunction has been associated with an increased risk of cardiovascular events. 23 ) Cardiovascular disease has also been a major cause of mortality in COPD patients. 24) Recent studies have found that treatment with inhaled tiotropium reduced the risk for cardiovascular events and cardiovascular mortality in COPD patients. 25) However, the mechanism of this effect has not been clear. The beneficial effect of tiotropium on LV diastolic dysfunction can partly explain the reduction in the risk for cardiovascular events in COPD patients with inhaled tiotropium treatment.
This pilot study had some methodological limitations and selected patients characteristics that may limit the external validity and broad applicability of the present findings. Only patients with mild LV diastolic dysfunction were eligible to participate in this study. Moreover, this study included a very small sample size, no control group, and relatively short follow-up duration. Therefore, additional investigations with a larger number of patients from multiple institutions are necessary to be able to generalize the findings obtained here.
Conclusion
The present study is the first to show that treatment with inhaled tiotropium may be effective not only for pulmonary function but also for LV diastolic function in COPD patients in the chronic phase after pulmonary resection. Additional studies are warranted to determine whether these effects can be observed in COPD patients without surgery and translated into improved clinical outcomes.
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